Published: 2017-05-23

Comparative analysis of cutaneous drug reactions among different fluoroquinolones: an experimental study

Susandhya Devadarshini, Kali Prasad Pattnaik, Rajashree Samal, Jigyansa Mohapatra, Swayam Sourav Sahoo


Background: Fluoroquinolones are generally well tolerated; most adverse effects are mild and common are GI upset. But recent literatures suggest increase reports of Cutaneous Drug reactions (CDRs) including SJS with Fluoroquinolones. However there is insufficient data both in animal and clinical study regarding comparative Analysis of CDRs among different Fluoroquinolones. Hence the present study was under taken to evaluate incidence of comparative CDRs among different Fluoroquinolones.

Methods: 96 Albino mice were divided into 16 groups of 6 each. Ciprofloxacin, Ofloxacin, Levofloxacin and Moxifloxacin were administered in Group 1-4, 5-8, 9-12 and 13-16 at the dose of 50/100/150/200mg/kg respectively. The following parameters were observed i.e. Number and % of mice developed CDRs with type and severity. Duration of exposure till development of CDRs, time to Recovery and Mortality in each group.

Results: Ofloxacin produced maximum number of CDRs i.e. in 33.3% mice which was significantly higher than that with levofloxacin (p=0.006*). The incidence of CDRs with Ciprofloxacin was 16.67 % and Moxifloxacin16.67 %, but no statistically significant difference than Ofloxacin. The onset for CDRs was significantly earlier with Ofloxacin among the Fluoroquinolones (P=0.013*). The reactions varied from severe dermatitis to serious exfoliation of the skin with ofloxacin and Ciprofloxacin, Alopecia with Moxifloxacin but no cutaneous reactions to Levofloxacin. Mortality was found only with Ofloxacin (12.5%).

Conclusions: CDRs are common and may present as severe skin exfoliation or Alopecia with Fluoroquinolones. The CDRs are Maximum with Ofloxacin without significant difference from ciprofloxacin but significantly higher than levofloxacin which has least potential for CDRs. Fatality may occur with Ofloxacin.


Cutaneous drug reactions, Fluoroquinolones, Epidermal necrolysis, Mice model

Full Text:



Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137:765-70.

Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 1999;21:407-21.

Childs S. Safety of the fluoroquinolone antibiotics; focus on the molecular structure. Infect Urol. 2000;13:3-10.

Naveen KN, Pai VV, Rai V, Athanikar SB. Retrospective analysis of Steven Johnson syndrome and toxic epidermal necrolysis over a period of 5 years from northern Karnataka, India. Indian J Pharmacol. 2013;45(1):80-2.

Leone R, Venegoni M, Motola D. Adverse Drug Reactions Related to the Use of Fluoroquinolone Antimicrobials. Drug Safety. 2003;26(2):109.

Patel TK, Thakkar SH, Sharma DC. Cutaneous adverse drug reactions in Indian population: A systematic review. Indian Dermatology Online Journal, 2014.

Saito N, Yoshioka N, Abe R, Qiao H, Fujita Y, Hoshina D, et al. Stevens- Johnson Syndrome/Toxic Epidermal Necrolysis Mouse Model Generated by Using PBMCs and the Skin of Patients. J Allergy Clin Immunol. 2012;131(2):9.

Sharma MR, Werth B, Werth VP. Animal models of acute photodamage: comparisons of anatomic, cellular and molecular responses in C57BL/6J, SKH1 and Balb/c mice. Photochem Photobiol. 2011;87(3):690-8.

Sun J, Silva KA, McElwee KJ, King LE, Sundberg JP. The C3H/HeJ mouse and DEBR rat models for alopecia areata: review of preclinical drug screening approaches and results; Exp Dermatol. 2008 Oct;17(10):793-805.

Snejina G, Vasilev, Mateev G, Lawrence CP. Antimicrobial Photosensitive reactions: Arch Intern Med. 1998;158(18):1993-2000.

FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects, issued on May 12, 2016. Safety Announcement [7-26-2016]. Accessed FDA web site ( on 8.4.2016.

Owen K. Comparative Grepafloxacin photo toxicity in mouse skin: Journal of Antimicrobial Chemotherapy. 1998(42):261-4.

Petri WA. Sulfonamide3s, Trimethoprime-Sulphamethoxazole, Quinolones, and Agents for Urinary Tract Infections, in: Laurence L. Brunton, Brue A. Chabner Editors. Goodman and Gillman’s, The Pharmacological Basis of Therapeutics. 25th Ed. New York, NY: McGraw-Hill; 2011:1463-1476.

Leone R, Venegoni M, Motola D. Adverse Drug Reactions Related to the Use of Fluoroquinolone Antimicrobials An Analysis of Spontaneous Reports and Fluoroquinolone consumption Data from Three Italian Regions: Drug Safety. 2003;26(2):109-20.

Kulthanan K, Chularojanamontri L, Manapajon A, Dhana N, Jongjarearnprasert K. Cutaneous adverse reactions to fluoroquinolones Dermatitis. 2011 May;22(3):155-60.

Vigi- Access: Global Database of suspected adverse drug reactions (ADRs), maintained by the Uppsala Monitoring Centre. Available from: